ethyl (2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoate | 477982-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoate
• CAS: 477982-30-2
• 化学式: C₂₇H₃₀O₆
• 分子量: 450.532
• InChiKey: YMNSPVQQIGDOAO-SANMLTNESA-N

物化性质

• 沸点：
  577.0±50.0 °C(Predicted)
• 密度：
  1.142±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  33
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl (2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoate 在 sodium hydroxide 作用下， 生成 2-甲氧基-3-[4-[3-(4-苯氧基苯氧基)丙氧基]苯基]丙酸
  参考文献：
  名称：

  An Asymmetric Synthesis of PPAR-? Agonist Navaglitazar from (+)-Methyl (2S,3R)-3-(4-methoxyphenyl)glycidate

  摘要：

  这段文字的中文翻译如下：

  描述了一种从商业上可获得的(+)-甲基(2S,3R)-3-(4-甲氧基苯基)环氧乙酸酯合成纳瓦格利塞的不对称合成方法，纳瓦格利塞是一种过氧化物酶体增殖物激活受体(PPAR)α激动剂。这种新合成方法具有高总收率、低溶剂使用量、结晶中间体和操作简便的特点。

  DOI：

  10.2533/chimia.2006.580
• 作为产物：
  描述：

  4-苯氧基苯酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 生成 ethyl (2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoate
  参考文献：
  名称：

  2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents

  摘要：

  Herein we describe a series of potent and selective PPARgamma agonists with moderate PPARalpha affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.042

文献信息

• Modulators of peroxisome proliferator activated receptors
  申请人：Brooks Alisa Dawn

  公开号：US20070276138A1

  公开（公告）日：2007-11-29

  Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH 2 — or —CH 2 CH 2 —; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R 1 and W. R 1 is —(CH 2 ) n —CH(OR 2 )—(CH 2 ) m E, —(CH)═C(OR 2 )—(CH 2 ) m E, —(CH 2 ) n —CH(Y)—(CH 2 ) m E or —(CH)═C(Y)—(CH 2 ) m E; wherein E is COOR 3 , C 1 -C 3 -alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C 1 -C 6 alkyl, haloalkyl and aryl-C 0-4 -alkyl; R 2 is —H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR 4 , —COOR 4 , —CONR 5 R 6 , —C(S)R 4 , —C(S)OR 4 or —C(S)NR 5 R 6 . R 3 is —H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is —O—, —CH 2 —, —CH 2 CH 2 — or —CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R 1 . R 4 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.

  公开了一种化合物，其结构式表示为（I）：其中Ar是取代或未取代的芳香族基团。Q是共价键，-CH2-或-CH2CH2-；W是取代或未取代的烷基或取代或未取代的异烷基连接基团，长度为两到十个原子，优选长度为两到七个原子。苯环A可以选择性地用最多四个取代基取代R1和W。R1是-(CH2)n-CH(OR2)-(CH2)mE，-(CH)=C(OR2)-(CH2)mE，-(CH2)n-CH(Y)-(CH2)mE或-(CH)=C(Y)-(CH2)mE；其中E是COOR3，C1-C3-烷基腈，羧酰胺，磺酰胺，酰基磺酰胺或四唑，其中磺酰胺，酰基磺酰胺和四唑可以选择性地用一个或多个取代基取代，独立地选自C1-C6烷基，卤代烷基和芳基-C0-4-烷基；R2是-H，一种脂肪基，一种取代的脂肪基，卤代烷基，一种芳香基，一种取代的芳香基，-COR4，-COOR4，-CONR5R6，-C（S）R4，-C（S）OR4或-C（S）NR5R6；R3是-H，一种脂肪基，一种取代的脂肪基，一种芳香基或一种取代的芳香基；Y是-O-，-CH2-，-CH2CH2-或-CH═CH-，并与苯环A中与R1正交的碳原子键合；R4-R6独立地是-H，一种脂肪基，一种取代的脂肪基，一种芳香基或一种取代的芳香基；n和m独立地为0、1或2。
• Bioorg. Med. Chem. Lett. 2005, 15, 51-55
  作者：

  DOI：——

  日期：——
• US7192982B2
  申请人：——

  公开号：US7192982B2

  公开（公告）日：2007-03-20
• 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents
  作者：José A. Martín、Dawn A. Brooks、Lourdes Prieto、Rosario González、Alicia Torrado、Isabel Rojo、Beatriz López de Uralde、Carlos Lamas、Rafael Ferritto、María Dolores Martín-Ortega、Javier Agejas、Francisco Parra、John R. Rizzo、Gary A. Rhodes、Roger L. Robey、Charles A. Alt、Samuel R. Wendel、Tony Y. Zhang、Anne Reifel-Miller、Chahrzad Montrose-Rafizadeh、Joseph T. Brozinick、Eric Hawkins、Elizabeth A. Misener、Daniel A. Briere、Robert Ardecky、James D. Fraser、Alan M. Warshawsky

  DOI：10.1016/j.bmcl.2004.10.042

  日期：2005.1

  Herein we describe a series of potent and selective PPARgamma agonists with moderate PPARalpha affinity and little to no affinity for other nuclear receptors. In vivo studies in a NIDDM animal model (ZDF rat) showed that these compounds are efficacious at low doses in glucose normalization and plasma triglyceride reduction. Compound 1b (LY519818) was selected from our SAR studies to be advanced to clinical evaluation for the treatment of type II diabetes. (C) 2004 Elsevier Ltd. All rights reserved.
• An Asymmetric Synthesis of PPAR-? Agonist Navaglitazar from (+)-Methyl (2S,3R)-3-(4-methoxyphenyl)glycidate
  作者：John R. Rizzo、Tony Y. Zhang

  DOI：10.2533/chimia.2006.580

  日期：——

  An asymmetric synthesis of navaglitazar, a peroxisome proliferator activated receptor (PPAR) ? agonist, from commercially available (+)-methyl (2S,3R)-3-(4-methoxyphenyl)glycidate, is described. The new synthesis features high overall yield, low solvent usage, crystalline intermediates and operational simplicity.

  这段文字的中文翻译如下：

  描述了一种从商业上可获得的(+)-甲基(2S,3R)-3-(4-甲氧基苯基)环氧乙酸酯合成纳瓦格利塞的不对称合成方法，纳瓦格利塞是一种过氧化物酶体增殖物激活受体(PPAR)α激动剂。这种新合成方法具有高总收率、低溶剂使用量、结晶中间体和操作简便的特点。